Bipolar disorder is a serious condition that can cause significant impairment in patients’ lives. As such, it is important to ensure good treatment and management of the condition. However, adherence to pharmacological treatment is a significant problem, and risks of non‐adherence include hospitalization and suicide. Both antipsychotic medications and mood stabilisers are recommended for the maintenance treatment of bipolar disorder. According to the Canadian Network for Mood and Anxiety Treatment (CANMAT) 2018 guidelines, psychoeducation should be provided initially to reduce non‐adherence to medication. If this is ineffective, long‐acting injectable (LAI) antipsychotics should be considered (1). The CANMAT guidelines also state that most patients with bipolar disorder will require short or long‐term combination treatment to address acute or subsyndromal symptoms and to reduce rates of recurrence.

中文翻译：

---

两种长效注射剂（LAI）在双相情感障碍的维持治疗中同时使用

躁郁症是一种严重状况，可能导致患者生活严重受损。因此，重要的是要确保对疾病的良好治疗和管理。但是，坚持药物治疗是一个重大问题，不坚持的风险包括住院和自杀。推荐抗精神病药和情绪稳定剂用于双相情感障碍的维持治疗。根据《加拿大情绪和焦虑症治疗网络（CANMAT）2018指南》，应首先提供心理教育以减少对药物的不依从性。如果这种方法无效，则应考虑使用长效注射（LAI）抗精神病药（1）。